Status:
COMPLETED
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Congenital Amegakaryocytic Thrombocytopenia
Diamond-blackfan Anemia
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them...
Detailed Description
OBJECTIVES: Primary * Determine the engraftment rate with reduced toxicity ablative conditioning regimen comprising alemtuzumab, fludarabine, and busulfan followed by allogeneic stem cell transplant...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following hematologic conditions:
- Aplastic anemia with marrow aplasia, meeting all of the following criteria:
- Absolute neutrophil count \< 500/mm\^3
- Platelet and/or red cell transfusion dependent
- Chronic aplastic anemia, meeting all of the following criteria:
- Transfusion dependent
- Unresponsive to immunosuppressive therapy
- Alternative matched unrelated donor has been identified
- Congenital marrow failure syndrome, including any of the following (with closely matched related or unrelated donor):
- Primary red cell aplasia (Diamond-Blackfan syndrome)
- Congenital neutropenia (Kostmann's syndrome)
- Amegakaryocytic thrombocytopenia
- Congenital dyserythropoietic anemias
- Other severe acquired cytopenias in which a transplantation using a combined busulfan/cyclophosphamide conditioning regimen is indicated
- Hemoglobinopathy (with closely matched related or unrelated donor)
- β-thalassemia major
- Sickle cell anemia
- Hemoglobin E/β-thalassemia
- Severe immunodeficiency disease
- Chediak-Higashi disease
- Wiskott-Aldrich syndrome
- Combined immunodeficiency disease (Nezelof's)
- Hyper immunoglobulin M (IgM) syndrome
- Bare lymphocyte syndrome
- Chronic granulomatous disease
- Familial erythrohemophagocytic lymphohistiocytosis
- Other stem cell defects (e.g., osteopetrosis)
- Severe immune dysregulation/autoimmune disorders
- Achieved a transient response to prior immunosuppressive therapy
- Chronic myelogenous leukemia
- Disease in first chronic phase
- Acute myeloid leukemia
- Disease in first remission
- Myelodysplastic syndromes
- Inborn errors of metabolism
- Histiocytosis
- No severe combined immunodeficiency disease
- Matched related or unrelated donor available by high resolution DNA typing
- Related donor, meeting both of the following criteria:
- Matched at both human leukocyte antigen (HLA)-Drβ1 alleles
- No more than 1 mismatch at the 4 HLA-A and -B alleles
- Unrelated donor, meeting 1 of the following criteria:
- Marrow matched at both HLA-Drβ1 alleles AND no more than 1 mismatch at the 4 HLA-A and -B alleles
- Umbilical cord blood matched at 5/6 HLA-A, -B, and -DRβ1 alleles with at least 1 -DRβ1 match AND there are ≥ 3x10\^5 CD34+ (Cluster of differentiation 34-positive) cells per kg body weight of recipient available at the time of cryopreservation
- PATIENT CHARACTERISTICS:
- Cardiac ejection fraction ≥ 27%
- Creatinine clearance ≥ 50 mL/min by 24-hour urine collection or glomerular filtration rate
- DLCO (diffusion capacity of lung for carbon monoxide) ≥ 50% of predicted (corrected for anemia/lung volume)
- PRIOR CONCURRENT THERAPY:
- No prior transplantation for leukemia from which patient remains engrafted and alemtuzumab is not needed as part of the conditioning regimen
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00301834
Start Date
January 1 2005
End Date
September 1 2011
Last Update
September 28 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
2
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792-6164